Consistent with colon tumors in AOM/DSS-treated mice, trametinib treatment decreased the percentage of Ki67+ cells and, conversely, increased the percentage of CC3+ cells (Fig. 7e, f). This evidence concerns the gene MKI67 and colonic neoplasm.